Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekten af ​​lokalt leverede allogene mesenkymale stromaceller

1. november 2026 opdateret af: Ali R Djalilian, University of Illinois Chicago

Effekten af ​​lokalt leverede allogene mesenkymale stamceller til at fremme hornhindereparation

The proposed Conventional Cohort Expansion Study involves the use of Mesenchymal Stromal Cells (MSCs) are derived from the bone marrow. We previously studied the safety of subconjunctival injection of allogeneic bone marrow-derived MSCs in patients with nonhealing epitheliopathy (IRB Protocol 2020-0334). In the present study, we want to study the efficacy of this treatment on chronic epitheliopathies.

Studieoversigt

Status

Rekruttering

Betingelser

Detaljeret beskrivelse

The "Efficacy of Locally Delivered Allogeneic Mesenchymal Stem Cells for Promoting Corneal Repair Study" otherwise known as the "MSC Study," is designed to assess the safety of allogeneic bone marrow-derived MSC secreted factor on the ocular surface via subconjunctival injection of MSC, and also obtain a preliminary observation on the following:

  • Epithelial barrier integrity and/or wound closure.
  • Development of Scarring.
  • Final Visual Acuity.

The objective is to improve clinical outcomes in significant non-healing corneal wounds. To achieve these goals, the MSC Study will include a Phase II efficacy study.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

38

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Ali R Djalilian, MD
  • Telefonnummer: 312-996-8937
  • E-mail: adjalili@uic.edu

Undersøgelse Kontakt Backup

  • Navn: Charlotte E Joslin, OD, PhD
  • Telefonnummer: 312-996-5410
  • E-mail: charjosl@uic.edu

Studiesteder

    • Illinois
      • Chicago, Illinois, Forenede Stater, 60612
        • Rekruttering
        • Department of Ophthalmology and Visual Sciences
        • Kontakt:
        • Kontakt:
          • Charlotte E Joslin, OD, PhD
          • Telefonnummer: 312-996-5410
          • E-mail: charjosl@uic.edu
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21201
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Aktiv, ikke rekrutterende
        • Mass Eye and Ear Infirmary
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Aktiv, ikke rekrutterende
        • University of Pennsylvania, Scheie Eye Institute

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

Ocular Health:

  • Patients with non-resolving corneal epitheliopathy or epithelial defect after two or more weeks of standard non-surgical treatments (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops; anti-inflammatory therapy, soft bandage contact lens).
  • No objective clinical evidence of improvement in the last 2 weeks (≤50% reduction in fluorescein staining or ≤50% reduction in longest diameter of the epithelial defect).
  • If both eyes have chronic epithelial disease, the eye with the worse epithelial disease will be treated.
  • Evidence of impaired epithelial barrier manifested by fluorescein staining of the epithelium with a score 6 or higher by National Eye Institute grading.
  • Patients with stage 1 (no epithelial defect), stage 2 (persistent epithelial defect, PED; without stromal loss) or stage 3 (corneal ulcer; with stromal loss) neurotrophic keratopathy25-27 limited to ≤80% corneal diameter.

Study Procedures:

  • Only patients who satisfy all Informed Consent requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by patients and/or legal representatives must have been approved by the IRB for the current study.
  • Patients must have the ability and willingness to comply with study procedures.

Exclusion Criteria:

Visual Acuity:

Ocular Health:

  • Ocular drug toxicity less than two weeks ago
  • Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation in the affected eye.
  • History of any ocular surgery (including laser or refractive surgical procedures) in the affected eye within the three months before study enrollment. (An exception to the preceding statement will be allowed if the ocular surgery is considered to be the cause of the PED. Ocular surgery in the affected eye will not be allowed during the study treatment period and elective ocular surgery procedures should not be planned during the duration of the follow-up period unless the patient will be involved in corneal thinning of more than 1/3 corneal stroma, corneal melting or perforation.
  • Prior surgical procedure(s) for the treatment of a chronic corneal epitheliopathy (e.g., complete tarsorrhaphy, conjunctival flap, etc.) in the affected eye with the exception of amniotic membrane transplantation. Patients previously treated with amniotic membrane transplantation may only be enrolled two weeks after the membrane has disappeared within the area of the chronic corneal epitheliopathy or corneal ulcer or at least six weeks after the date of the amniotic membrane transplantation procedure. Patients previously treated with Botox (botulinum toxin) injections used to induce pharmacologic blepharoptosis are eligible for enrollment only if the last injection was given at least 90 days prior to enrollment in the study.
  • Chronic corneal epitheliopathy in the background of endothelial decompensation that needs corneal graft
  • Anticipated need for punctual occlusion during the study treatment period. Patients with punctual occlusion or punctual plugs inserted prior to the study are eligible for enrollment provided that the punctual occlusion is maintained during the study.
  • Evidence of corneal ulceration involving the posterior third of the corneal stroma, corneal melting or perforation in the affected eye.
  • Presence or history of any ocular or systemic disorder or condition that might hinder the efficacy of the study treatment or its evaluation, could possibly interfere with the interpretation of study results, or could be judged by the investigator to be incompatible with the study visit schedule or conduct (e.g., progressive or degenerative corneal or retinal conditions, uveitis, optic neuritis, poorly controlled diabetes, autoimmune disease, systemic infection, neoplastic diseases).
  • Patients with uncontrolled eyelid abnormality that preclude appropriate eyelid closure or including eyelash abnormality

Study Procedures:

  • Known hypersensitivity to one of the components of the study or procedural medications (e.g., fluorescein).
  • History of drug, medication or alcohol abuse or addiction.
  • Use of any investigational agent within 4 weeks of screening visit.
  • Participation in another clinical study at the same time as the present study.
  • Participants who are pregnant at the time of study enrollment will be excluded; pregnancy is identified according to the patient's self-report /positive βhCG

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Medium dose of allogenic MSC drops

Dose of allogeneic MSC subconjunctival injection will be assigned 3,000,000 cells/150 µL.

Subconjunctival Injection of Allogeneic Mesenchymal Stromal Cellsmasked clinical trial, patients with non-resolving corneal epithelial disease (i.e., refractory to standard treatments for at least two weeks) will receive a single subconjunctival injection of bone marrow-derived allogeneic MSCs or vehicle (CS5 freezing media, BioLife Solutions Inc, Bothell, WA, USA), with continued follow-up for up to 90 days.

Sham-komparator: Control Group

For the control group, 50 µL of the freezing media (vehicle) will be injected.

For the control group, 150 µL of injectable normal saline (0.9% NaCl). will be injected.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Improvement of Corneal Epithelial Barrier and/or Integrity (Efficacy Rate)
Tidsramme: Day 28

The proportion of patients with improved epithelial barrier and/or integrity from baseline to DAY 28 as determined by the investigator on slit lamp examination:

  • Improved epithelial barrier, defined as a 50 % improvement in corneal fluorescein staining score
  • Improved epithelial integrity, defined as a healed epithelial defect
Day 28

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Visual Acuity
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Percent change in best-corrected distance visual acuity from baseline to DAY 90, as measured using standard ETDRS protocols

Baseline, Days 1-7, 28, 60, 90
Corneal staining and NEI grading
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Grading of fluorescein staining of the cornea

Baseline, Days 1-7, 28, 60, 90
Ocular Surface Parameters
Tidsramme: Baseline, Day 28, 90

Changes in tear breakup time (TBUT), ocular surface disease index (OSDI), Lissamine green staining, and anesthetic Schirmer's test from baseline to DAY 28 and DAY 90

Baseline, Day 28, 90
Corneal Epithelial Thickness
Tidsramme: Day 28, 90

Percent change in corneal epithelial thickness from baseline to DAY 28 and DAY 90, as measured by anterior segment OCT (AS-OCT)

Day 28, 90
Patient Symptoms
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Changes in ocular discomfort visual analog scale (VAS) 0 - 100, where 0 is no discomfort and 100 the worst discomfort, from baseline to DAY 90

Baseline, Days 1-7, 28, 60, 90
Time to epithelial healing
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Time of improvement of epitheliopathy

Baseline, Days 1-7, 28, 60, 90
Corneal Scar
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Change in the size of corneal scar (if present) from baseline to DAY 90, as documented by slit lamp photographs

Baseline, Days 1-7, 28, 60, 90
Corneal Neo-vascularization
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Change in corneal vascularization on slit lamp photographs from baseline to DAY 90

Baseline, Days 1-7, 28, 60, 90
Conjunctival injection
Tidsramme: Baseline, Days 1-7, 28, 60, 90

Change in conjunctival injection on slit lamp examination from baseline to DAY 90

Baseline, Days 1-7, 28, 60, 90

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Ali R Djalilian, MD, University of Illinois Chicago
  • Ledende efterforsker: Charlotte E Joslin, OD, PhD, University of Illinois Chicago

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. september 2023

Primær færdiggørelse (Anslået)

28. december 2026

Studieafslutning (Anslået)

28. december 2026

Datoer for studieregistrering

Først indsendt

21. januar 2023

Først indsendt, der opfyldte QC-kriterier

21. januar 2023

Først opslået (Faktiske)

30. januar 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. november 2026

Sidst verificeret

1. december 2025

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2022-0751
  • W81XWH-18-1-0661 (Andet bevillings-/finansieringsnummer: United States Department of Defense)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner